Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite

European Journal of Clinical Pharmacology

Volumn 52, Issue 5, 1997, Pages 403-406

  Lukkari, E ^a,b   Juhakoski, A ^a   Aranko, K ^a   Neuvonen, P J ^b  

^a Oy Leiras Finland Ab   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Drug interaction; Itraconazole; N Desethyloxybutynin; Oxybutynin; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; ITRACONAZOLE; OXYBUTYNIN; PLACEBO;

ADULT; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CHOLINERGIC ANTAGONISTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG SYNERGISM; FEMALE; HUMANS; ITRACONAZOLE; MALE; MANDELIC ACIDS;

EID: 0030742992     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050309     Document Type: Article

References (17)

1. Aaltonen L, Allonen H, Iisalo E, Juhakoski A, Kleimola T, Sellman R (1984) Antimuscarinic activity of oxybutynin in the human plasma quantitated by a radioreceptor assay. Acta Pharmacol Toxicol 55: 100-103
2. Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, Herchuelz A (1988) The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 35: 515-520
3. Hughes KM, Lang JC, Lazare R, Gordon D, Stanton SL, Malone-Lee J, Geraint M (1992) Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly subjects. Xenobiotica 22: 859-869
4. Lindeke B, Hallstrom G, Johansson C, Ericsson Ö, Olsson L-I, Strömberg S (1981) Metabolism of oxybutynin: establishment of desethyl oxybutynin and oxybutynin-N oxide formation in rat liver preparation using deuterium substitution and gas chromatographic mass spectrometric analysis. Biomed Mass Spectrom 8: 506-513
5. Yaich M, Popon M, Jacqz Aigrain E (1995) The metabolism of oxybutynin is dependent on CYP3A and not on CYP2D6 (abstract) Therapie 50 [Suppl]: 67
6. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen PJ (1993) Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 45: 191-193
7. Crane JK, Shih HT (1993) Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 95: 445-446
8. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, Neuvonen P (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53: 298-305
9. Varhe A, Olkkola K and Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56: 601-607
10. Neuvonen PJ, Jalava K-M (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastalin acid. Clin Pharmacol Ther 60: 54-61
11. Jalava K-M, Olkkola KT, Neuvonen PJ (1997) Itraconazole greatly increases plasma concentrations and effects of felodipin. Clin Pharmacol Ther 61: 410-415
12. Allenmark S, Edebo A, Lindgren K (1990) Determination of itraconazole in serum with high-performance liquid chromatography. J Chromatogr 532: 203-206
13. Remmel RP, Dombrowskis D, Canafax DM (1988) Assay of itraconazole in leucemic patient plasma by reverse-phase small-bore liquid chromatography. J Chromatogr 432: 388-394
14. Jones B, Kenward MG (1989) Design and Analysis of Cross-Over Trials. Chapman and Hall, London, pp 30-60
15. Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55: 481-485
16. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ (1994) Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37: 221-225
17. Varhe A, Olkkola KT, Neuvonen PJ (1996) Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 59: 369-375